KR20250112793A - 2-아자비시클로[3.1.1]헵탄 화합물 - Google Patents

2-아자비시클로[3.1.1]헵탄 화합물

Info

Publication number
KR20250112793A
KR20250112793A KR1020257019334A KR20257019334A KR20250112793A KR 20250112793 A KR20250112793 A KR 20250112793A KR 1020257019334 A KR1020257019334 A KR 1020257019334A KR 20257019334 A KR20257019334 A KR 20257019334A KR 20250112793 A KR20250112793 A KR 20250112793A
Authority
KR
South Korea
Prior art keywords
group
compound
methyl
azabicyclo
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020257019334A
Other languages
English (en)
Korean (ko)
Inventor
아키타케 야마구치
나오히로 다케모토
가오루 마츠시타
준 고바야시
마사하루 이누이
마사히로 이노우에
슌스케 마에하라
šœ스케 마에하라
고지 아베
Original Assignee
다이이찌 산쿄 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 다이이찌 산쿄 가부시키가이샤 filed Critical 다이이찌 산쿄 가부시키가이샤
Publication of KR20250112793A publication Critical patent/KR20250112793A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020257019334A 2022-12-16 2023-12-15 2-아자비시클로[3.1.1]헵탄 화합물 Pending KR20250112793A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JPJP-P-2022-201488 2022-12-16
JP2022201488 2022-12-16
PCT/JP2023/044987 WO2024128305A1 (ja) 2022-12-16 2023-12-15 2-アザビシクロ[3.1.1]ヘプタン化合物

Publications (1)

Publication Number Publication Date
KR20250112793A true KR20250112793A (ko) 2025-07-24

Family

ID=91485946

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020257019334A Pending KR20250112793A (ko) 2022-12-16 2023-12-15 2-아자비시클로[3.1.1]헵탄 화합물

Country Status (8)

Country Link
EP (1) EP4635944A1 (cg-RX-API-DMAC7.html)
JP (1) JPWO2024128305A1 (cg-RX-API-DMAC7.html)
KR (1) KR20250112793A (cg-RX-API-DMAC7.html)
CN (1) CN120603816A (cg-RX-API-DMAC7.html)
AU (1) AU2023395547A1 (cg-RX-API-DMAC7.html)
MX (1) MX2025006722A (cg-RX-API-DMAC7.html)
TW (1) TW202430169A (cg-RX-API-DMAC7.html)
WO (1) WO2024128305A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20260012686A (ko) * 2024-07-18 2026-01-27 (주)셀트리온 신규한 오렉신 2 수용체 작용제 및 이의 용도

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015088000A1 (ja) 2013-12-12 2015-06-18 国立大学法人筑波大学 スルホンアミド誘導体またはその薬学的に許容される酸付加塩
WO2017135306A1 (en) 2016-02-04 2017-08-10 Takeda Pharmaceutical Company Limited Substituted piperidine compound and use thereof
WO2019027058A1 (en) 2017-08-03 2019-02-07 Takeda Pharmaceutical Company Limited HETEROCYCLIC COMPOUND AND USE THEREOF
WO2020158958A1 (en) 2019-01-31 2020-08-06 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
WO2020167701A1 (en) 2019-02-13 2020-08-20 Merck Sharp & Dohme Corp. Pyrrolidine orexin receptor agonists
WO2021108628A1 (en) 2019-11-25 2021-06-03 Alkermes, Inc. Substituted macrocyclic compounds and related methods of treatment
WO2021107023A1 (ja) 2019-11-27 2021-06-03 大日本住友製薬株式会社 シクロアルキルウレア誘導体
WO2022014680A1 (ja) 2020-07-17 2022-01-20 エーザイ・アール・アンド・ディー・マネジメント株式会社 置換ピペリジン化合物及びその用途
WO2022051596A1 (en) 2020-09-03 2022-03-10 Orexia Therapeutics Limited Bicyclic-heterocycle derivatives and their uses as orexin-2 receptor agonists

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015056100A2 (en) 2013-10-14 2015-04-23 Marvell World Trade Ltd. Systems and methods for graphics process units power management
JP6359924B2 (ja) 2014-09-17 2018-07-18 トヨタ自動車株式会社 非接触送受電システム
CA3074059A1 (en) * 2017-09-01 2019-03-07 Chronos Therapeutics Limited Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists
WO2019081939A1 (en) * 2017-10-25 2019-05-02 Chronos Therapeutics Limited 2-AZABICYCLO [3.1.1] DERIVATIVES AS ANTAGONISTS OF OREXIN-1 AND OREXIN-2 RECEPTORS
CN116969888A (zh) * 2022-04-24 2023-10-31 优领医药科技(上海)有限公司 含环丙基并环类衍生物、其药学上可接受的盐及其制备方法和应用

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015088000A1 (ja) 2013-12-12 2015-06-18 国立大学法人筑波大学 スルホンアミド誘導体またはその薬学的に許容される酸付加塩
WO2017135306A1 (en) 2016-02-04 2017-08-10 Takeda Pharmaceutical Company Limited Substituted piperidine compound and use thereof
WO2019027058A1 (en) 2017-08-03 2019-02-07 Takeda Pharmaceutical Company Limited HETEROCYCLIC COMPOUND AND USE THEREOF
WO2020158958A1 (en) 2019-01-31 2020-08-06 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
WO2020167701A1 (en) 2019-02-13 2020-08-20 Merck Sharp & Dohme Corp. Pyrrolidine orexin receptor agonists
WO2021108628A1 (en) 2019-11-25 2021-06-03 Alkermes, Inc. Substituted macrocyclic compounds and related methods of treatment
WO2021107023A1 (ja) 2019-11-27 2021-06-03 大日本住友製薬株式会社 シクロアルキルウレア誘導体
WO2022014680A1 (ja) 2020-07-17 2022-01-20 エーザイ・アール・アンド・ディー・マネジメント株式会社 置換ピペリジン化合物及びその用途
WO2022051596A1 (en) 2020-09-03 2022-03-10 Orexia Therapeutics Limited Bicyclic-heterocycle derivatives and their uses as orexin-2 receptor agonists

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
Cell, 92, 1998, 573 - 585
Cell, 98, 1999, 365 - 376
Cell, 98, 1999, 437 - 451
Chem. Res. Toxicol. 17, 2004, 3 - 16
CNS Drugs, 27, 2013, 83 - 90
Curr. Opin. Drug Discovery Dev. 4, 2001, 55 - 59
Lancet, 355, 2000, 39 - 40
Neuron, 38, 2003, 715 - 730
Proc. Natl. Acad. Sci. USA, 101, 2004, 4649 - 4654

Also Published As

Publication number Publication date
CN120603816A (zh) 2025-09-05
JPWO2024128305A1 (cg-RX-API-DMAC7.html) 2024-06-20
EP4635944A1 (en) 2025-10-22
WO2024128305A1 (ja) 2024-06-20
AU2023395547A1 (en) 2025-06-26
TW202430169A (zh) 2024-08-01
MX2025006722A (es) 2025-07-01

Similar Documents

Publication Publication Date Title
CN108026056B (zh) 作为组蛋白脱乙酰酶6抑制剂的1,3,4-噁二唑酰胺衍生物化合物及其药物组合物
US8153658B2 (en) Piperidine derivative or salt thereof
JP2011513474A (ja) カテプシンs阻害剤としてのフロ[3,2−b]ピロール−3−オン
PL207041B1 (pl) Pochodna cyklopropylo-skondensowanej pirolidyny jako inhibitor dipeptydylopeptydazy IV i jej zastosowanie oraz kompozycja farmaceutyczna
CA3210873A1 (en) Compounds, compositions, and methods of using the same
JP2009513523A (ja) ベンゼンスルホニルアミノ化合物およびそれらを含む医薬組成物
AU2006226554B2 (en) 3, 4-substituted pyrrolidine derivatives for the treatment of hypertension
KR20020082896A (ko) 프로테아제 억제제
JP7810788B2 (ja) コロナウイルス感染症の治療又は予防のための3clプロテア-ゼ小分子阻害剤及びその用途
TWI851890B (zh) 抗病毒性1,3-二氧代茚化合物
KR20070088806A (ko) 레닌의 활성에 의존적인 질환의 치료를 위한 피롤리딘유도체
KR20200139702A (ko) 칼페인 조정자 및 그 치료학적 용도
US20250221966A1 (en) Rxfp1 agonists
CN118525003A (zh) 作为kv7.2抑制剂的新型杂芳基脲化合物
WO2023243601A1 (ja) アザシクロアルキルカルボニル環状アミン化合物
WO2024128305A1 (ja) 2-アザビシクロ[3.1.1]ヘプタン化合物
US12115157B2 (en) 3-phenoxyazetidin-1-yl-heteroaryl pyrrolidine derivatives and the use thereof as medicament
CN101300226B (zh) 对组蛋白脱乙酰酶具有抑制活性的烷基氨甲酰基萘氧基辛烯酰基羟基酰胺衍生物及其制备方法
KR101950057B1 (ko) 파록세틴 유도체
JPWO2005068427A1 (ja) カルボキサミド誘導体およびその用途
JP2004526662A (ja) プロテアーゼ阻害剤
US20030114437A1 (en) Protease inhibitors
JP2009502739A (ja) タキキニン受容体拮抗剤としてのピペリジン誘導体
JP2017141224A (ja) 医薬組成物
KR100814092B1 (ko) 히스톤 디아세틸라제 저해활성을 갖는 알킬카바모일나프탈렌일옥시 옥테노일 하이드록시아마이드 유도체, 이의제조방법 및 이를 유효성분으로 하는 항암제용 약학조성물

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

Q12 Application published

Free format text: ST27 STATUS EVENT CODE: A-1-1-Q10-Q12-NAP-PG1501 (AS PROVIDED BY THE NATIONAL OFFICE)